<DOC>
	<DOCNO>NCT02605057</DOCNO>
	<brief_summary>Given LEO 80185 gel take effect upper layer skin , important compare examine amount drug upper layer skin Dovobet® Ointment . Therefore , dermatopharmacokinetic study conduct healty adult male volunteer evaluate pharmacokinetics LEO 80185 gel Dovobet® Ointment stratum corneum . In trial , single application LEO 80185 gel Dovobet® ointment apply multiple test sit back healthy Japanese male adult trial design compare amount active ingredient steady state close-to-steady state LEO 80185 gel Dovobet® Ointment . The amount calcipotriol betamethasone dipropionate stratum corneum assess use tape stripping .</brief_summary>
	<brief_title>Dermatopharmacokinetic Trial LEO 80185 Gel</brief_title>
	<detailed_description>The study consist two phase : The pilot : The first part , know pilot study , include 8 subject evaluate pharmacokinetic profile LEO 80185 gel Dovobet® Ointment measure amount active ingredient stratum corneum . Pivotal : The second part , know pivotal study , design compare amount active ingredient steady state close-to-steady state LEO 80185 gel Dovobet® Ointment . The number subject pivotal study number application site study medication base result pilot study . The number subject include trial design trial line previous type DPK trial Japan Japanese guideline</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Signed date informed consent form obtain . 2 . Healthy Japanese male subject accord medical history , physical examination , ECG , vital sign laboratory test . 3 . Aged 20 40 year inclusive . 4 . Subjects enough skin area application investigational product . 1 . Body Mass Index outside range 1825 kg/m² 2 . History presence alcohol drug abuse . 3 . History allergic reaction medication . 4 . Subjects , history , systemic cutaneous disease could way confound interpretation trial result ( e.g . atopic dermatitis , eczema , psoriasis ) 5 . Known suspected hypersensitivity component LEO 80185 gel Dovobet® ointment . 6 . Known suspected hepatic , renal cardiac disorder . 7 . Known suspected disorder calcium metabolism associate hypercalcaemia albumincorrected serum calcium reference range sample take screening . 8 . Subjects follow skin diseases/skin abnormality impede assessment application site ( back ) : eczema/dermatitis abnormal pigmentation bruise scar inflammation due sunburn history and/or presence skin allergy atopic dermatitis history drug hypersensitivity Signs skin irritation/disease/disorders/symptoms blemish plan site application ( e.g . erythema , dryness , roughness , scaling , scar , mole , sunburn ) 9 . Subjects suspect infection base infection test result sample take screening ( Hepatitis B surface antigen , HCV antibiody , HIV antigen/antibody , serological test syphilis ) . 10 . Use systemic , locally inject inhaled corticosteroid within 4 week Day 1 . 11 . Use vitamin D calcium supplement , systemic vitamin D analogue within 4 week Day 1 . 12 . Use medication ( systemic topical ) within 2 week Day 1 . 13 . Subjects receive treatment nonmarketed drug substance ( i.e . agent yet make available clinical use follow registration ) within 4 month Day 1 . 14 . Current participation interventional clinical trial . 15 . Previously randomise clinical trial . 16 . Previous current photoinduced photoaggravated disease ( e.g . abnormal response sunlight ) . 17 . Exposure excessive chronic ultraviolet radiation ( e.g . sunlight , sun lamp , tan booth phototherapy ) within 4 week Day 1 . 18 . In opinion ( sub ) investigator , participation trial inappropriate .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>